Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients

(2020) Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. Journal of Thrombosis and Haemostasis. pp. 815-824. ISSN 15387933 (ISSN)

Full text not available from this repository.

Abstract

Background: Congenital fibrinogen deficiency is an ultra-rare disorder in which patients can experience severe and/or frequent bleeding episodes (BEs). Here, we present the largest prospective study to date on the treatment of this disorder. Methods: Hemostatic efficacy of human fibrinogen concentrate (HFC; FIBRYGA®, Octapharma AG) for treatment of bleeding or surgical prophylaxis was assessed by investigators and adjudicated by an independent data monitoring and endpoint adjudication committee (IDMEAC) according to a four-point scale, using objective criteria. Thromboelastometry maximum clot firmness (MCF) was also determined. Results: Twenty-five afibrinogenemia patients were treated with HFC: 24 for on-demand treatment of 89 BEs, and nine as prophylaxis for 12 surgeries. For BEs, treatment success (rating of excellent or good) evaluated by investigators was 96.6 (90 confidence interval CI, 0.92-0.99; two missing ratings, classified as failures) and by the IDMEAC was 98.9% (90% CI, 0.95-0.999). Mean ± standard deviation (SD) increase in MCF was 5.8 ± 2.5 mm one hour after the first HFC infusion (mean ± SD dose, 61.88 ± 11.73 mg/kg). For the 12 surgeries (median range HFC dose/surgery, 85.80 mg/kg 34.09-225.36), intraoperative and postoperative treatment success were both rated 100% (90% CI, 0.82-1.00) by investigators and the IDMEAC. Three adverse events were possibly treatment related, including a moderate case of thrombosis. There were no deaths, no severe allergic or hypersensitivity reactions, and no clinical evidence of neutralizing antifibrinogen antibodies. Conclusions: Human fibrinogen concentrate was efficacious for on-demand treatment of bleeding and as surgical prophylaxis, with a favorable safety profile, in patients with congenital afibrinogenemia. © 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis

Item Type: Article
Keywords: afibrinogenemia fibrinogen hemostasis surgical prophylaxis thrombelastography acetylsalicylic acid analgesic agent fibrinogen concentrate hemostatic agent adolescent adult Article bleeding brain hemorrhage chemoprophylaxis child drug efficacy drug eruption drug safety female fibrinogen blood level fibrinogen defect gastrointestinal hemorrhage hemarthrosis human immunogenicity in vivo study intervention study ischemia loading drug dose maintenance drug dose male multicenter study muscle bleeding open study oral bleeding pain peroperative care phase 3 clinical trial phlebitis postoperative care priority journal prospective study skin discoloration skin manifestation thromboelastometry thrombogenicity thrombosis vagina bleeding thromboelastography Hemostatics Humans Prospective Studies
Subjects: WH Hemic and Lymphatic Systems > WH 120-540 Hematologic Diseases. Immunologic Factors. Blood Banks
Divisions: Other
Page Range: pp. 815-824
Journal or Publication Title: Journal of Thrombosis and Haemostasis
Journal Index: Scopus
Volume: 18
Number: 4
Identification Number: https://doi.org/10.1111/jth.14727
ISSN: 15387933 (ISSN)
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/13027

Actions (login required)

View Item View Item